Dual oxidase 1: A predictive tool for the prognosis of hepatocellular carcinoma patients

Chen,Shengsen; Ling,Qingxia; Yu,Kangkang; Huang,Chong; Li,Ning; Zheng,Jianming; Bao,Suxia; Cheng,Qi; Zhu,Mengqi; Chen,Mingquan

doi:10.3892/or.2016.4745

Dual oxidase 1: A predictive tool for the prognosis of hepatocellular carcinoma patients

Authors:
- Shengsen Chen
- Qingxia Ling
- Kangkang Yu
- Chong Huang
- Ning Li
- Jianming Zheng
- Suxia Bao
- Qi Cheng
- Mengqi Zhu
- Mingquan Chen
View Affiliations

Affiliations: Department of Infectious Diseases and Hepatology, Huashan Hospital, Fudan University, Shanghai 200040, P.R. China
Published online on: April 14, 2016 https://doi.org/10.3892/or.2016.4745
Pages: 3198-3208
Copyright: © Chen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Dual oxidase 1 (DUOX1), which is the main source of reactive oxygen species (ROS) production in the airway, can be silenced in human lung cancer and hepatocellular carcinomas. However, the prognostic value of DUOX1 expression in hepatocellular carcinoma patients is still unclear. We investigated the prognostic value of DUOX1 expression in liver cancer patients. DUOX1 mRNA expression was determined in tumor tissues and non-tumor tissues by real‑time PCR. For evaluation of the prognostic value of DUOX1 expression, Kaplan-Meier method and Cox's proportional hazards model (univariate analysis and multivariate analysis) were employed. A simple risk score was devised by using significant variables obtained from the Cox's regression analysis to further predict the HCC patient prognosis. We observed a reduced DUOX1 mRNA level in the cancer tissues in comparison to the non‑cancer tissues. More importantly, Kaplan-Meier analysis showed that patients with high DUOX1 expression had longer disease-free survival and overall survival compared with those with low expression of DUOX1. Cox's regression analysis indicated that DUOX1 expression, age, and intrahepatic metastasis may be significant prognostic factors for disease-free survival and overall survival. Finally, we found that patients with total scores of >2 and >1 were more likely to relapse and succumb to the disease than patients whose total scores were ≤2 and ≤1. In conclusion, DUOX1 expression in liver tumors is a potential prognostic tool for patients. The risk scoring system is useful for predicting the survival of liver cancer patients after tumor resection.

View Figures

View References

1	Yang JD and Roberts LR: Hepatocellular carcinoma: A global view. Nat Rev Gastroenterol Hepatol. 7:448–458. 2010. View Article : Google Scholar : PubMed/NCBI
2	Sakamoto M: Early HCC: Diagnosis and molecular markers. J Gastroenterol. 44(Suppl 19): 108–111. 2009. View Article : Google Scholar : PubMed/NCBI
3	Roy K, Wu Y, Meitzler JL, Juhasz A, Liu H, Jiang G, Lu J, Antony S and Doroshow JH: NADPH oxidases and cancer. Clin Sci (Lond). 128:863–875. 2015. View Article : Google Scholar
4	De Deken X, Wang D, Many MC, Costagliola S, Libert F, Vassart G, Dumont JE and Miot F: Cloning of two human thyroid cDNAs encoding new members of the NADPH oxidase family. J Biol Chem. 275:23227–23233. 2000. View Article : Google Scholar : PubMed/NCBI
5	Fischer H: Mechanisms and function of DUOX in epithelia of the lung. Antioxid Redox Signal. 11:2453–2465. 2009. View Article : Google Scholar : PubMed/NCBI
6	Luxen S, Belinsky SA and Knaus UG: Silencing of DUOX NADPH oxidases by promoter hypermethylation in lung cancer. Cancer Res. 68:1037–1045. 2008. View Article : Google Scholar : PubMed/NCBI
7	Pulcrano M, Boukheris H, Talbot M, Caillou B, Dupuy C, Virion A, De Vathaire F and Schlumberger M: Poorly differentiated follicular thyroid carcinoma: Prognostic factors and relevance of histological classification. Thyroid. 17:639–646. 2007. View Article : Google Scholar : PubMed/NCBI
8	Ling Q, Shi W, Huang C, Zheng J, Cheng Q, Yu K, Chen S, Zhang H, Li N and Chen M: Epigenetic silencing of dual oxidase 1 by promoter hypermethylation in human hepatocellular carcinoma. Am J Cancer Res. 4:508–517. 2014.PubMed/NCBI
9	Tong L, Chuang CC, Wu S and Zuo L: Reactive oxygen species in redox cancer therapy. Cancer Lett. 367:18–25. 2015. View Article : Google Scholar : PubMed/NCBI
10	Sablina AA, Budanov AV, Ilyinskaya GV, Agapova LS, Kravchenko JE and Chumakov PM: The antioxidant function of the p53 tumor suppressor. Nat Med. 11:1306–1313. 2005. View Article : Google Scholar : PubMed/NCBI
11	D'Autréaux B and Toledano MB: ROS as signalling molecules: Mechanisms that generate specificity in ROS homeostasis. Nat Rev Mol Cell Biol. 8:813–824. 2007. View Article : Google Scholar : PubMed/NCBI
12	Bhattacharyya S and Saha J: Tumour, oxidative stress and host t cell response: Cementing the dominance. Scand J Immunol. 82:477–488. 2015. View Article : Google Scholar : PubMed/NCBI
13	Cabello CM, Bair WB III and Wondrak GT: Experimental therapeutics: Targeting the redox Achilles heel of cancer. Curr Opin Investig Drugs. 8:1022–1037. 2007.PubMed/NCBI
14	Fruehauf JP and Meyskens FL Jr: Reactive oxygen species: A breath of life or death? Clin Cancer Res. 13:789–794. 2007. View Article : Google Scholar : PubMed/NCBI
15	Nagasue N, Kohno H, Chang YC, Taniura H, Yamanoi A, Uchida M, Kimoto T, Takemoto Y, Nakamura T and Yukaya H: Liver resection for hepatocellular carcinoma. Results of 229 consecutive patients during 11 years. Ann Surg. 217:375–384. 1993. View Article : Google Scholar : PubMed/NCBI
16	Edge SB and Compton CC: The American Joint Committee on Cancer: The 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010. View Article : Google Scholar : PubMed/NCBI
17	Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009. View Article : Google Scholar
18	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar
19	Gokcan H, Savaş N, Oztuna D, Moray G, Boyvat F and Haberal M: Predictors of survival in hepatocellular carcinoma patients. Ann Transplant. 20:596–603. 2015. View Article : Google Scholar : PubMed/NCBI
20	Hwang S, Lee YJ, Kim KH, Ahn CS, Moon DB, Ha TY, Song GW, Jung DH and Lee SG: The impact of tumor size on long-term survival outcomes after resection of solitary hepatocellular carcinoma: Single-institution experience with 2558 patients. J Gastrointest Surg. 19:1281–1290. 2015. View Article : Google Scholar : PubMed/NCBI
21	Nickel A, Kohlhaas M and Maack C: Mitochondrial reactive oxygen species production and elimination. J Mol Cell Cardiol. 73:26–33. 2014. View Article : Google Scholar : PubMed/NCBI
22	Ramsey MR and Sharpless NE: ROS as a tumour suppressor? Nat Cell Biol. 8:1213–1215. 2006. View Article : Google Scholar : PubMed/NCBI
23	Berndtsson M, Hägg M, Panaretakis T, Havelka AM, Shoshan MC and Linder S: Acute apoptosis by cisplatin requires induction of reactive oxygen species but is not associated with damage to nuclear DNA. Int J Cancer. 120:175–180. 2007. View Article : Google Scholar
24	Taylor WR and Stark GR: Regulation of the G2/M transition by p53. Oncogene. 20:1803–1815. 2001. View Article : Google Scholar : PubMed/NCBI
25	Kao WY, Chao Y, Chang CC, Li CP, Su CW, Huo TI, Huang YH, Chang YJ, Lin HC and Wu JC: Prognosis of early-stage hepatocellular carcinoma: The clinical implications of substages of Barcelona Clinic Liver Cancer System based on a cohort of 1265 patients. Medicine (Baltimore). 94:e19292015. View Article : Google Scholar
26	Hahn WC and Weinberg RA: Rules for making human tumor cells. N Engl J Med. 347:1593–1603. 2002. View Article : Google Scholar : PubMed/NCBI